182 related articles for article (PubMed ID: 37125259)
41. CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias.
Taneja A; Jain T
EJHaem; 2022 Jan; 3(Suppl 1):32-38. PubMed ID: 35844301
[TBL] [Abstract][Full Text] [Related]
42. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Meir J; Abid MA; Abid MB
Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
44. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.
Davis JA; Gaffney KJ; McGann M; Smith D; Edwards K; Baldino E; Bakos K; Butcher C; Greenwell B; Hess BT; Hashmi H
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e14-e18. PubMed ID: 36319568
[TBL] [Abstract][Full Text] [Related]
45. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
46. Special Education: Aplastic Anemia.
Teramura M; Mizoguchi H
Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
[TBL] [Abstract][Full Text] [Related]
47. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study.
Gagelmann N; Wulf GG; Duell J; Glass B; van Heteren P; von Tresckow B; Fischer M; Penack O; Ayuk F; Einsele H; Holtick U; Thomson J; Dreger P; Kröger N
Blood Adv; 2023 Feb; 7(4):555-559. PubMed ID: 35696759
[TBL] [Abstract][Full Text] [Related]
48. The EHA Research Roadmap: Transfusion Medicine.
Stanworth SJ; Brand A; Kaveri SV; Vrielink H; Greinacher A; Domanović D; von Lindern M; Allard S; Bayry J; Bohonek M; Buser A; Claas FHJ; Knutson F; Lozano M; Olsson ML; Pirenne F; Rebulla P; So-Osman C; Tissot JD; Toye AM; Ushiro-Lumb I; van den Akker E; Zeerleder S
Hemasphere; 2022 Feb; 6(2):e670. PubMed ID: 35098039
[No Abstract] [Full Text] [Related]
49. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
[TBL] [Abstract][Full Text] [Related]
50. [Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC].
Picard M; Sterin A; Bay JO; Courbon C; Moreau AS; Paul F; Pochon C; Tudesq JJ; Vicente C; Yakoub-Agha M; Yakoub-Agha I
Bull Cancer; 2023 Feb; 110(2S):S123-S131. PubMed ID: 35094839
[TBL] [Abstract][Full Text] [Related]
51. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
[TBL] [Abstract][Full Text] [Related]
52. The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders.
Eichinger S; Morange PE; Cattaneo M; Fretigny M; Rauch A; van Hylckama Vlieg A; Trégouët DA; Ruf W; Levi M; Páramo JA; van der Poll T; Kyrle PA; Garagiola I; Peyvandi F
Hemasphere; 2021 Oct; 5(10):e643. PubMed ID: 34522845
[No Abstract] [Full Text] [Related]
53. Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma.
Du M; Huang L; Kou H; Li C; Hu Y; Mei H
Front Immunol; 2022; 13():898341. PubMed ID: 35784357
[TBL] [Abstract][Full Text] [Related]
54. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.
Li Y; Ming Y; Fu R; Li C; Wu Y; Jiang T; Li Z; Ni R; Li L; Su H; Liu Y
Front Pharmacol; 2022; 13():950923. PubMed ID: 36313336
[TBL] [Abstract][Full Text] [Related]
55. Investigation and Management of Bone Mineral Density Following Hematopoietic Cell Transplantation: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.
Salooja N; Greinix H; Ruutu T; van der Werf S; van Biezen A; Lawitschka A; Basak G; Duarte R
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1955-1962. PubMed ID: 32623077
[TBL] [Abstract][Full Text] [Related]
56. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
57. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Jiang H; Hu Y; Mei H
Biomark Res; 2020 Nov; 8(1):66. PubMed ID: 33292685
[TBL] [Abstract][Full Text] [Related]
58. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
59. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
60. [Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Paul F; Vicente C; Courbon C; Moreau AS; Picard M; Pochon C; Sterin A; Tudesq JJ; Yakoub-Agha M; Bay JO; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S90-S97. PubMed ID: 34876272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]